全文获取类型
收费全文 | 74273篇 |
免费 | 2969篇 |
国内免费 | 3014篇 |
专业分类
耳鼻咽喉 | 472篇 |
儿科学 | 1901篇 |
妇产科学 | 3407篇 |
基础医学 | 5790篇 |
口腔科学 | 2434篇 |
临床医学 | 7242篇 |
内科学 | 10593篇 |
皮肤病学 | 653篇 |
神经病学 | 1952篇 |
特种医学 | 3733篇 |
外科学 | 5600篇 |
综合类 | 14265篇 |
一般理论 | 9篇 |
预防医学 | 7677篇 |
眼科学 | 1477篇 |
药学 | 4988篇 |
5篇 | |
中国医学 | 5112篇 |
肿瘤学 | 2946篇 |
出版年
2023年 | 223篇 |
2022年 | 345篇 |
2021年 | 369篇 |
2020年 | 383篇 |
2019年 | 236篇 |
2018年 | 446篇 |
2017年 | 418篇 |
2016年 | 471篇 |
2015年 | 522篇 |
2014年 | 751篇 |
2013年 | 1232篇 |
2012年 | 1709篇 |
2011年 | 4546篇 |
2010年 | 2703篇 |
2009年 | 2013篇 |
2008年 | 2490篇 |
2007年 | 2250篇 |
2006年 | 2344篇 |
2005年 | 3342篇 |
2004年 | 7743篇 |
2003年 | 7053篇 |
2002年 | 5566篇 |
2001年 | 4446篇 |
2000年 | 2651篇 |
1999年 | 3460篇 |
1998年 | 2541篇 |
1997年 | 2312篇 |
1996年 | 1624篇 |
1995年 | 1406篇 |
1994年 | 1422篇 |
1993年 | 1938篇 |
1992年 | 1704篇 |
1991年 | 1489篇 |
1990年 | 1130篇 |
1989年 | 961篇 |
1988年 | 744篇 |
1987年 | 623篇 |
1986年 | 635篇 |
1985年 | 351篇 |
1984年 | 217篇 |
1983年 | 201篇 |
1982年 | 136篇 |
1981年 | 146篇 |
1980年 | 138篇 |
1979年 | 137篇 |
1977年 | 129篇 |
1976年 | 124篇 |
1975年 | 131篇 |
1974年 | 102篇 |
1973年 | 101篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Journal of Chinese Pharmaceutical Sciences 《中国药学》2020,29(12):829-831
A biography of Academician Zhicen Lou. 相似文献
12.
13.
14.
15.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
16.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
17.
18.
Bi-Hua BIE Yong CHEN Zhi-Qi ZHAO Institute of Neurobiology Fu-Dan University Shanghai China Institute of Shanghai Physiology Chinese Academy of Sciences Shanghai China 《中国神经科学杂志》2006,(2)
Objective Ligustrazine, also named as tetramethylpyrazine, is a compound purified from Ligusticum chuanxiong hort and has ever been testified to be a calcium antagonist. The present investigation was to determine the antinoci-ceptive effect of ligustrazine and, if any, the peripheral ionic mechanism involved. Methods Paw withdrawal Latency ( PWL) to noxious heating was measured in vivo and whole-cell patch recording was performed on small dorsal root ganglion (DRG) neurons. Results Intraplantar injection of ligustrazine (0.5 mg in 25μl) significantly prolonged the withdrawal latency of ipsilateral hindpaw to noxious heating in the rat. Ligustrazine not only reversibly inhibited high-voltage gated calcium current of dorsal root ganglion (DRG) neuron in dose-dependent manner with IC50 of 1.89 mmol/L, but also decreased tetrodotoxin (TTX) -resistant sodium current in relatively selective and dose-dependent manner with IC50 of 2.49 mmol/L. Conclusion The results suggested that ligustrazine could elevate the threshold of thermal nociception through inhibiting the high-voltage gated calcium current and TTX-resistant sodium current of DRG neuron in the rat. 相似文献
19.
20.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献